Feedback plc Stock
Your prediction
Pros and Cons of Feedback plc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Feedback plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Feedback plc | 0.740% | 0.000% | 119.355% | -55.556% | -32.000% | -93.200% | -88.667% |
| Cfc Industriebeteiligungen | -8.740% | -5.243% | -7.925% | -31.268% | 25.128% | -66.345% | -41.905% |
| Allerthal-werke-Ag | 0.000% | -0.775% | 8.475% | 25.490% | 18.519% | 8.475% | -9.859% |
| Blockmate Ventures Inc. | 17.520% | -12.406% | -20.478% | -65.481% | -53.400% | -85.159% | -85.159% |
News
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type
